DOP2009000272A - Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit - Google Patents

Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit

Info

Publication number
DOP2009000272A
DOP2009000272A DO2009000272A DO2009000272A DOP2009000272A DO P2009000272 A DOP2009000272 A DO P2009000272A DO 2009000272 A DO2009000272 A DO 2009000272A DO 2009000272 A DO2009000272 A DO 2009000272A DO P2009000272 A DOP2009000272 A DO P2009000272A
Authority
DO
Dominican Republic
Prior art keywords
methods
compositions
adenilil
cyclase
inhibit
Prior art date
Application number
DO2009000272A
Other languages
English (en)
Inventor
Catherine H Schein
Deliang Chen
Scott R Gilbertson
Maria Estrella-Jimenez
Jian Gao
Mary Ann Walter
Johnny W Peterson
Original Assignee
Mission Pharma Co
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40468705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2009000272(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mission Pharma Co, Univ Texas filed Critical Mission Pharma Co
Publication of DOP2009000272A publication Critical patent/DOP2009000272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pequeñas moleculas y sus derivados son descritos para el tratamiento y/o prevencion de la perdida de fluido intestinal. Son tambien descritos metodos para el uso de dichas moleculas y sus derivados para tratar y/o prevenir condiciones asociadas con el incremento de los niveles de 3',5;-monofosfato de adenosina. Composiciones especificas de la invercion son tambien nuevas.
DO2009000272A 2007-06-15 2009-12-03 Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit DOP2009000272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94437507P 2007-06-15 2007-06-15
US3526908P 2008-03-10 2008-03-10

Publications (1)

Publication Number Publication Date
DOP2009000272A true DOP2009000272A (es) 2010-02-15

Family

ID=40468705

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000272A DOP2009000272A (es) 2007-06-15 2009-12-03 Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit

Country Status (12)

Country Link
US (2) US8003692B2 (es)
EP (1) EP2166841A4 (es)
CN (1) CN101784274A (es)
AR (1) AR067850A1 (es)
AU (1) AU2008302667B2 (es)
BR (1) BRPI0813176A2 (es)
CA (1) CA2692004C (es)
CL (1) CL2008001782A1 (es)
CO (1) CO6270184A2 (es)
DO (1) DOP2009000272A (es)
MX (1) MX2009013676A (es)
WO (1) WO2009038842A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9095578B2 (en) * 2007-01-12 2015-08-04 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
WO2008121171A1 (en) * 2007-01-12 2008-10-09 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for antibacterial interventions
BRPI0813176A2 (pt) * 2007-06-15 2014-12-30 Mission Pharma Co Moléculas e composições par ainibir fator edema e adenilil ciclase
EP2326953B1 (en) * 2008-07-22 2018-03-21 Promega Corporation Adp detection based luminescent phosphotransferase or atp hydrolase assay
CA2757615C (en) * 2009-03-31 2018-07-17 Renascience Co., Ltd. Plasminogen activator inhibitor-1 inhibitor
CA2860672A1 (en) 2012-01-06 2013-07-11 University Of South Florida Compositions, methods of use, and methods of treatment
US10092537B2 (en) 2013-04-15 2018-10-09 Renascience Co., Ltd. Use for PAI-1 inhibitor
US9677117B2 (en) 2014-10-08 2017-06-13 Promega Corporation Bioluminescent succinate detection assay
CN105218343B (zh) * 2015-10-26 2017-03-22 乐普药业股份有限公司 一种3‑溴环己‑2‑烯‑1‑酮的合成方法
EP3568388A4 (en) * 2017-01-10 2020-10-14 Owen-Barry Pharmaceuticals Inc. ANTICONVULSIVING COMPOUNDS
MX2020003242A (es) 2017-09-22 2020-09-18 Jubilant Epipad LLC Compuestos heterociclicos como inhibidores de pad.
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
TWI904890B (zh) * 2024-10-14 2025-11-11 明志科技大學 鋅金屬有機框架材料及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066834A (en) * 1974-01-24 1978-01-03 Miles Laboratories, Inc. Cycloalkenyl analogues of prostaglandins E
US4222944A (en) * 1978-07-31 1980-09-16 Hoffmann-La Roche Inc. Halo-3-dibenzofuran alkanonitriles
CA2256631A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
WO2000056341A1 (en) 1999-03-22 2000-09-28 Charterhouse Therapeutics Ltd. Chemical compounds and their uses
AU2001274858A1 (en) * 2000-06-08 2001-12-17 Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
WO2002040481A2 (en) * 2000-11-20 2002-05-23 Millennium Pharmaceuticals, Inc. Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
WO2002056879A1 (en) * 2001-01-03 2002-07-25 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
MXPA04001253A (es) * 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
EP1456214A2 (en) * 2001-12-14 2004-09-15 Charterhouse Therapeutics Limited Improvements in pharmaceutical compositions
US20030157159A1 (en) * 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
US20030224403A1 (en) * 2002-02-27 2003-12-04 Popov Serguei G. Lethal toxin cytopathogenicity and novel approaches to anthrax treatment
BR0306292A (pt) * 2002-02-28 2004-08-24 Japan Tobacco Inc Composto de éster e uso medicinal do mesmo
EA010408B1 (ru) * 2002-10-23 2008-08-29 Гленмарк Фармасьютикалс Лтд. Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы
CA2528626A1 (en) * 2003-07-09 2005-01-20 Biolipox Ab Indoles useful in the treatment of inflammation
WO2005028467A1 (en) * 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
RS56037B1 (sr) * 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
US20080096848A1 (en) * 2004-09-29 2008-04-24 Cytovia Inc. Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as Activators of Caspases and Inducers of Apoptosis
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
WO2007076055A2 (en) * 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2007135120A1 (en) * 2006-05-23 2007-11-29 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
BRPI0813176A2 (pt) * 2007-06-15 2014-12-30 Mission Pharma Co Moléculas e composições par ainibir fator edema e adenilil ciclase

Also Published As

Publication number Publication date
AU2008302667A1 (en) 2009-03-26
CA2692004C (en) 2013-04-09
CN101784274A (zh) 2010-07-21
MX2009013676A (es) 2010-06-01
AR067850A1 (es) 2009-10-28
US8003692B2 (en) 2011-08-23
US20090093519A1 (en) 2009-04-09
CL2008001782A1 (es) 2008-11-03
AU2008302667B2 (en) 2014-07-10
EP2166841A2 (en) 2010-03-31
WO2009038842A2 (en) 2009-03-26
US20120010233A1 (en) 2012-01-12
BRPI0813176A2 (pt) 2014-12-30
WO2009038842A3 (en) 2009-12-30
EP2166841A4 (en) 2014-05-07
CA2692004A1 (en) 2009-03-26
CO6270184A2 (es) 2011-04-20

Similar Documents

Publication Publication Date Title
DOP2009000272A (es) Metodos y composiciones para inhibir el factor de edema y la adenilil ciclasa y kit
ECSP088774A (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricación.
ECSP109953A (es) Derivados de piridazinona
EA200802213A1 (ru) Способы лечения заболеваний крови
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
DOP2013000315A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
EA201100447A1 (ru) Органические соединения
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
ECSP10010361A (es) Derivados de piridazinona
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
NI201100108A (es) Nuevas pirazol - 4 - n - alcoxicarboxamidas como microbicidas.
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
BRPI0815708A8 (pt) composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
ECSP099071A (es) Agonistas de ep2
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
CR8879A (es) Bifeniltiazolcarboxamidas
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.